Database - (CIANE) | |
Description of this bibliographical database (CIANE website) |
https://ciane.net/id=2804 | ➡ Modify this record |
Bibliographical entry (without author) : | Off-label use of misoprostol for labor induction in Germany: A national survey - European Journal of Obstetrics Gynecology and Reproductive Biology - Vol. 187 - p.85-89 |
Author(s) : | Voigt, F.; Goecke, T.W.; Najjari, L.; Pecks, U.; Maass, N.; Rath, W. |
Year of publication : | 2015 |
URL(s) : | https://www.scopus.com/inward/record.uri?eid=2-s2.… |
Résumé (français) : |
|
Abstract (English) : | Objective Misoprostol is safe and effective for labor induction in viable pregnancies. Little is known about the prevalence of off-label use of misoprostol, and the reasons for using or not using misoprostol for labor induction. As such, a national survey was conducted in Germany to assess reliable data about the use of misoprostol in clinical practice. Study design A prospective study was performed in 2013 using a standardized survey questionnaire. All registered departments of obstetrics and gynecology in Germany were targeted. Results Out of 783 questionnaires, 542 (69%) were returned. Three hundred and fifty-five (66%) respondents reported that they use misoprostol for labor induction in viable term pregnancies, and 183 (34%) respondents reported that they never use misoprostol for this indication. The most common reasons given for using misoprostol in labor induction were: effectiveness (40%), good patient acceptance (35%), established/well proven in clinical practice (35%) and cost-effectiveness (32%). The most common reasons given for not using misoprostol were lack of licence (off-label use, 69%) and uncertainty of the legal situation (27%). Conclusion Although misoprostol is not licensed in Germany for obstetric indications, the vast majority of respondents (66%) reported that they use misoprostol for labor induction. The main reasons for not using misoprostol for labor induction in Germany are legal concerns rather than lack of scientific evidence. Cost-effective medications with evidence-based effectiveness and safety should be supported by a clear statement from national medical societies. © 2014 Elsevier Ireland Ltd. |
Sumário (português) : |
|
Resumen (español) : |
|
Comments : | |
Argument (français) : |
|
Argument (English): | |
Argumento (português): |
|
Argumento (español): |
|
Keywords : | |
Author of this record : | Import 26/11/2017 — 26 Nov 2017 |
Discussion (display only in English) | ||
---|---|---|
New expert query --- New simple query
Creating new record --- Importing records
User management --- Dump database --- Contact
This database created by Alliance francophone pour l'accouchement respecté (AFAR) is managed
by Collectif interassociatif autour de la naissance (CIANE, https://ciane.net).
It is fed by the voluntary contributions of persons interested in the sharing of scientific data.
If you agree with this project, you can support us in several ways:
(1) contributing to this database if you have a minimum training in documentation
(2) or financially supporting CIANE (see below)
(3) or joining any society affiliated with CIANE.
➡ Sign in or create an account to follow changes or become an editor.
➡ Contact bibli(arobase)ciane.net for more information.
Donating to CIANE (click “Faire un don”) will help us to maintain and develop sites and public databases towards the support of parents and caregivers’ informed decisions with respect to childbirth |